Epigenetic Alterations in Parathyroid Cancers

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Parathyroid cancers (PCas) are rare, accounting for ~0.005% of all cancers and are an infrequent cause of primary hyperparathyroidism.
• Approximately 90% of PCas are hormonally active, leading to severe hypercalcemia, and preoperative diagnosis is challenging due to overlapping features with benign lesions.
• Surgery offers the best cure, but recurrence rates approach 50%.

Purpose of the Study:

• To review current data on epigenetic alterations in parathyroid cancers.
• To highlight the distinction between parathyroid malignancies and benign parathyroid lesions based on epigenetic profiles.
• To provide insights into potential diagnostic and therapeutic targets.

Main Methods:

• Review of existing literature on epigenetic modifications in PCas.
• Analysis of studies focusing on DNA methylation, chromatin regulators, and microRNA expression.
• Synthesis of findings related to genetic anomalies like CDC73/HRPT2 mutations.

Main Results:

• PCas exhibit aberrant DNA methylation signatures and distinct microRNA expression profiles.
• These epigenetic changes suggest PCas are unique entities, differing from benign parathyroid tumors.
• Epigenetic signatures in PCas show similarities to some embryonic developmental aspects.

Conclusions:

• Epigenetic alterations, including DNA methylation and microRNA profiles, are key features distinguishing parathyroid cancers from benign lesions.
• Understanding these epigenetic differences is crucial for improved diagnosis and potential therapeutic strategies.
• Further research into epigenetic modifications may unlock new avenues for managing parathyroid cancer.